Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis - Summary - MDSpire

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis

  • By

  • María Velasco-de-Andrés

  • Pedro Puerta-Alcalde

  • Jiri Eitler

  • Lydia Krutz

  • Mariana Chumbita

  • Marta Español-Rego

  • Cristina Català

  • Laura Carrillo-Serradell

  • Violeta Planells-Romeo

  • Lucía Aragón-Serrano

  • Andrea Vergara

  • Amanda Isabel Pérez-Valencia

  • Patricia Monzó-Gallo

  • Antonio Gallardo-Pizarro

  • María Teresa Cibeira

  • Alexandru Vlagea

  • José Luis Caro

  • Eduard Palou

  • María Suárez-Lledó

  • Alex Soriano

  • Gonzalo Calvo

  • Álvaro Urbano-Ispizua

  • Torsten Tonn

  • Carolina Garcia-Vidal

  • Francisco Lozano

  • May 8, 2026

  • 0 min

Share

Objective:

To explore the potential of SRCD5CAR-NK-92 cells as a therapeutic option for treating multidrug-resistant invasive fungal infections (IFI), which pose significant challenges due to limited treatment options and high mortality rates.

Key Findings:
  • SRCD5CAR-NK-92 cells demonstrated superior antifungal activity compared to untransduced NK-92 cells, with a statistically significant increase in fungal clearance.
  • The patient received the treatment without significant adverse effects, such as cytokine storm or alloreactivity.
  • This case represents the first-in-human application of SRCD5CAR-NK-92 cells in treating severe MDR IFI, highlighting its potential.
Interpretation:

The study indicates that SRCD5CAR-NK-92 cells could be a safe and effective off-the-shelf therapeutic strategy for MDR fungal infections, warranting further research on efficacy, safety, and long-term outcomes.

Limitations:
  • The patient ultimately succumbed to the underlying hematological malignancy, which limited the assessment of treatment efficacy and the potential impact of the therapy.
  • Further studies are needed to evaluate the long-term outcomes and broader applicability of this therapy in diverse patient populations.
Conclusion:

The findings support the potential of SRCD5CAR-NK-92 cells as a novel therapeutic approach for treating multidrug-resistant fungal infections, underscoring the urgent need for additional clinical investigations to validate these results.

Original Source(s)

Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis

  • by María Velasco-de-Andrés, Pedro Puerta-Alcalde, Jiri Eitler, Lydia Krutz, Mariana Chumbita, Marta Español-Rego, Cristina Català, Laura Carrillo-Serradell, Violeta Planells-Romeo, Lucía Aragón-Serrano, Andrea Vergara, Amanda Isabel Pérez-Valencia, Patricia Monzó-Gallo, Antonio Gallardo-Pizarro, María Teresa Cibeira, Alexandru Vlagea, José Luis Caro, Eduard Palou, María Suárez-Lledó, Alex Soriano, Gonzalo Calvo, Álvaro Urbano-Ispizua, Torsten Tonn, Carolina Garcia-Vidal, Francisco Lozano

  • May 8, 2026

Related Content

Necrotizing Fasciitis Following Minor Bike Injury

Rapid progression from superficial abrasions to septic shock highlights diagnostic challenges and need for prompt multidisciplinary care.

Sepsis Antibiotic Timing Shows Physician Divide

Emergency department physicians differ in how quickly they initiate antibiotics for suspected sepsis.

Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children